연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
1977. Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk.
Lee JS1, Gu J1, Park HS1, Yoo HJ1, Kim HK1.
Clin Chem Lab Med. 2017 May 1;55(6):882-889. doi: 10.1515/cclm-2016-0676.
Link
1976. Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies.
Kim SY1, Gu JY1,2, Yoo HJ1,2, Kim JE1,2, Jang S3, Choe S3, Koh Y3, Kim I4, Kim HK1,5.
Ann Lab Med. 2017 Nov;37(6):484-493. doi: 10.3343/alm.2017.37.6.484.
Link
1975. A Novel ALAS2 Mutation Resulting in Variable Phenotypes and Pyridoxine Response in a Family with X-linked Sideroblastic Anemia.
Lee JS1,2, Gu J1,3, Yoo HJ1,3, Koh Y3,4, Kim HK5,3.
Ann Clin Lab Sci. 2017 May;47(3):319-322.
Link
1974. Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer.
Lee SH, Kim HP, Kang JK, Song SH, Han SW, Kim TY.
CANCER RES TREAT2017 Oct;49(4):1077-1087.
Link
1973. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS
J Clin Oncol. 2017 Sep 10;35(26):3065-3074. doi: 10.1200/JCO.2016.71.9096. Epub 2017 May 12.
Link
1972. Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.
Lee JK, Louzada S, An Y, Kim SY, Kim S, Youk J, Park S, Koo SH, Keam B, Jeon YK, Ku JL, Yang F, Kim TM, Ju YS.
Ann Oncol. 2017 Apr 1;28(4):890-897. doi: 10.1093/annonc/mdw686.
Link
1971. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, Keam B, Park HH, Kim DW, Kim CW, Heo DS.
Am J Pathol. 2017 May;187(5):980-986. doi: 10.1016/j.ajpath.2017.01.004. Epub 2017 Mar 9.
Link
1970. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Kim TM, Lee KW, Oh DY, Lee JS, Im SA, Kim DW, Han SW, Kim YJ, Kim TY, Kim JH, Han H, Kim WH, Bang YJ.
Cancer Res Treat. 2017 Aug 29. doi: 10.4143/crt.2017.303. [Epub ahead of print]
Link
1969. Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).
Kim HJ, Ock CY, Kim TM, Lee SH, Lee JY, Jung SH, Cho YS, Kim M, Keam B, Kim DW, Kim IH, Heo DS.
Cancer Res Treat. 2017 Jul 3. doi: 10.4143/crt.2017.051. [Epub ahead of print]
Link
1968. Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.
Son HY, Hwangbo Y, Yoo SK, Im SW, Yang SD, Kwak SJ, Park MS, Kwak SH, Cho SW, Ryu JS, Kim J, Jung YS, Kim TH, Kim SJ, Lee KE, Park DJ, Cho NH, Sung J, Seo JS, Lee EK, Park YJ, Kim JI
Nat Commun. 2017 Jul 13;8:15966. doi: 10.1038/ncomms15966.
Link